News | April 25, 2013

Toshiba Partners With Leading Universities for Advanced MR Research

Introduces new sequence development environment at ISMRM

April 25, 2013 — Leading research institutions are making breakthroughs in advanced magnetic resonance (MR) imaging with Toshiba America Medical Systems Inc.’s Vantage Titan 3.0T MR system. Toshiba has partnered with Shands at the University of Florida and the Keck Medical Center of the University of Southern California (USC) for MR clinical research in functional MRI (fMRI), as well as body and cardiac imaging.

 “We’re utilizing the Titan 3.0T MR to enhance visualization of cerebral spinal fluid (CSF) flow non-invasively and in the research of traumatic brain injuries from combat and athletics,” said Anthony Mancuso, professor and chairman of the department of radiology, UF College of Medicine. “The Titan 3.0T fulfills all the promises of a high-end 3.0T system, with high image quality, gradient homogeneity and patient-focused features.”

As part of Toshiba’s commitment to supporting institutions in advanced MR research, Toshiba is demonstrating the new sequence development environment (NSDE), a research-only tool that allows the research community to develop its own pulse sequences to explore new applications of MR imaging.

“Partnering with prestigious universities such as USC and Shands at the University of Florida illustrates our commitment to developing advanced technology that can expand the potential clinical applications of MR imaging,” said Suresh Narayan, senior manager, market development, MR business unit, Toshiba.

Toshiba showcased the Titan 3.0T with NSDE at this year’s International Society for Magnetic Resonance in Medicine (ISMRM) annual meeting in Salt Lake City, April 20-26, 2013.

For more information: www.medical.toshiba.com

Related Content

FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning
Technology | Artificial Intelligence | February 15, 2018
Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys...
AHRA and Canon Medical Systems Announce 2017 Putting Patients First Grant Winners
News | Patient Engagement | February 14, 2018
The Association for Medical Imaging Management (AHRA) and Canon Medical Systems recently announced the tenth annual...
Videos | Pediatric Imaging | February 14, 2018
ITN Associate Editor Jeff Zagoudis demonstrates several mobile apps designed to help pediatric patients learn what an
Patients Lack Information About Imaging Exams
News | Patient Engagement | February 14, 2018
Patients and their caregivers desire information about upcoming imaging examinations, but many are not getting it,...
Vantage Galan 3T XGO Edition MRI system was cleared by the FDA.
Technology | Magnetic Resonance Imaging (MRI) | February 12, 2018
February 12, 2018 — Physicians now have access to more neuro and cardiac...
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Overlay Init